A carregar...
The RAS-effector interaction as a drug target
About a third of all human cancers harbor mutations in one of the K-, N-, or HRAS genes that encode an abnormal RAS protein locked in a constitutively activated state to drive malignant transformation and tumor growth. Despite more than three decades of intensive research aimed at the discovery of R...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5243175/ https://ncbi.nlm.nih.gov/pubmed/28062402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0938 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|